Sign In
Buy OCX
$3.20
+0 (+0%)
At Close: Sep 16, 2025
Analyst Ratings for OncoCyte
08:01pm, Thursday, 01'st Dec 2022 Benzinga
OncoCyte (NASDAQ:OCX) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
1
2
0
0
Last 30D
0
0
Expert Ratings for OncoCyte
06:03pm, Thursday, 01'st Dec 2022 Benzinga
OncoCyte (NASDAQ:OCX) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
1
2
0
0
Last 30D
0
0
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
03:01pm, Thursday, 01'st Dec 2022 Benzinga
Upgrades
Northcoast Research upgraded the previous rating for SpartanNash Co (NASDAQ:SPTN) from Neutral to Buy. SpartanNash earned $0.55 in the third quarter, compared to $0.43 in the year-ago quarter
Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors
11:05pm, Wednesday, 30'th Nov 2022 GlobeNewswire Inc.
IRVINE, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights
Oncocyte Announces Executive Leadership Changes
11:00pm, Wednesday, 30'th Nov 2022 GlobeNewswire Inc.
IRVINE, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
04:58pm, Friday, 18'th Nov 2022 Benzinga
Upgrades
According to Summit Insights Group, the prior rating for Applied Materials Inc (NASDAQ:AMAT) was changed from Hold to Buy. For the fourth quarter, Applied Materials had an EPS of $2.03, comp
OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock?
05:00pm, Wednesday, 16'th Nov 2022 Zacks Investment Research
OncoCyte (OCX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock?
01:33pm, Wednesday, 16'th Nov 2022
OncoCyte (OCX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday
07:35am, Monday, 14'th Nov 2022 Benzinga
Gainers
ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday.
Shares of several companies in the broader industrial space traded higher on continued hopes of softer Fed p
OncoCyte (OCX) Reports Q3 Loss, Misses Revenue Estimates
11:05pm, Thursday, 10'th Nov 2022 Zacks Investment Research
OncoCyte (OCX) delivered earnings and revenue surprises of 38.46% and 32.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
OncoCyte Corporation (OCX) Q3 2022 Earnings Call Transcript
09:50pm, Thursday, 10'th Nov 2022
OncoCyte Corporation (NASDAQ:OCX ) Q3 2022 Results Conference Call November 10, 2022 4:30 PM ET Company Participants Caroline Corner - Investor Relations Ronnie Andrews - President and Chief Executive
Oncocyte Reports Third Quarter 2022 Financial Results
09:30pm, Thursday, 10'th Nov 2022 GlobeNewswire Inc.
IRVINE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights
OncoCyte (OCX) Reports Q3 Loss, Misses Revenue Estimates
07:33pm, Thursday, 10'th Nov 2022
OncoCyte (OCX) delivered earnings and revenue surprises of 38.46% and 32.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Oncocyte to Announce Third Quarter 2022 Financial Results
04:01pm, Thursday, 27'th Oct 2022
IRVINE, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights t
OncoCyte (OCX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
01:55pm, Monday, 26'th Sep 2022 Zacks Investment Research
After losing some value lately, a hammer chart pattern has been formed for OncoCyte (OCX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisio
